4-Sep-2026
TipRanks (Fri, 4-Sep 9:15 AM ET)
HUTCHMED Stock (HCM) Rallies Over 15% on a Major Licensing Deal
TipRanks (Thu, 3-Sep 9:57 AM ET)
HUTCHMED jumps 15% after licensing cancer therapy to GSK for up to $1.295B
Seeking Alpha News (Thu, 3-Sep 4:53 AM ET)
Novartis and Alteogen ink injectable drug delivery deal worth up to $3.2B
Seeking Alpha News (Wed, 2-Sep 12:47 PM ET)
Deutsche Bank Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
TipRanks (Wed, 2-Sep 7:05 AM ET)
4 stocks to watch on Tuesday: GSK, GPRO, DUOL, and MU
Seeking Alpha News (Tue, 1-Sep 9:00 AM ET)
J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
TipRanks (Tue, 1-Sep 7:35 AM ET)
Barclays Keeps Their Sell Rating on GlaxoSmithKline (GSK)
TipRanks (Tue, 1-Sep 2:45 AM ET)
GSK to advance mRNA seasonal flu vaccine to phase 3 trial
Seeking Alpha News (Tue, 1-Sep 2:33 AM ET)
PRNewswire (Mon, 24-Aug 1:06 PM ET)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) trades on the NYSE stock market under the symbol GSK.
As of September 4, 2026, GSK stock price declined to $49.89 with 2,111,338 million shares trading.
GSK has a beta of 0.25, meaning it tends to be less sensitive to market movements. GSK has a correlation of 0.01 to the broad based SPY ETF.
GSK has a market cap of $100.00 billion. This is considered a Large Cap stock.
Last quarter GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) reported $11 billion in Revenue and $1.35 earnings per share. This beat revenue expectation by $490 million and exceeded earnings estimates by $.08.
In the last 3 years, GSK traded as high as $61.70 and as low as $31.72.
The top ETF exchange traded funds that GSK belongs to (by Net Assets): AVDE, FENI, PPH, FVD, GMOI.
GSK has outperformed the market in the last year with a return of +30.5%, while the SPY ETF gained +19.8%. However, in the most recent history, GSK shares have underperformed the stock market with its stock returning -1.8% in the last 3 month period and -4.8% for the last 2 week period, while SPY has returned +2.0% and +0.6%, respectively.
GSK support price is $50.00 and resistance is $51.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GSK shares will trade within this expected range on the day.